key: cord-0915313-l9hkr40n
authors: Kaiser, Robert A.; Haller, Maria C.; Apfalter, Petra; Kerschner, Heidrun; Cejka, Daniel
title: Comparison of BNT162b2 (BioNTech/Pfizer) and mRNA-1273 (Moderna) SARS-CoV-2 mRNA vaccine immunogenicity in dialysis patients
date: 2021-07-13
journal: Kidney Int
DOI: 10.1016/j.kint.2021.07.004
sha: 7a8cd7f45fcceb067d0775a81abea1b0b1a696ff
doc_id: 915313
cord_uid: l9hkr40n

nan

11.4 ± 1.3 11.2 ± 1.5 11.5 ± 1.2 mean, SD Leukocytes (G/l) 6.4 (5.2-7.6) 6.6 (5.3-8.0) 6.4 (5.0-7.3) median, IQR

Patients with a history of SARS-CoV2-Infection (N=8; mRNA-1273: N=5, BNT-162b2: N=3) showed higher anti-S-antibody titers (median 9418, IQR 6114-11360 BAU/ml) than patients without prior SARS-CoV2-Infection (median: 1200, IQR 447-2275 BAU/ml).

Beta-coefficients ± 1.96 standard errors (SE) of the multivariate linear regression analysis with anti-S-antibody titers as the dependent variable.

Comparative Performance of Five Commercially Available Serologic Assays To Detect Antibodies to SARS-CoV-2 and Identify Individuals with High Neutralizing Titers

WHO International Standard for anti-SARS-CoV-2 immunoglobulin

We thank Mrs. Julia Panholzer for valuable administrative assistance and the dialysis staff of the OKL-Elisabethinen hospital for their technical support.